{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T06:10:48Z","timestamp":1726380648781},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jchromb.2024.124296","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T21:54:01Z","timestamp":1725141241000},"page":"124296","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Simultaneous determination of Obeticholic acid and its two major metabolites in human plasma after administration of Obeticholic acid tablets using ultra-high performance liquid chromatography tandem mass spectrometry"],"prefix":"10.1016","volume":"1246","author":[{"given":"Sha","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-ping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-ying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2024.124296_b0005","doi-asserted-by":"crossref","first-page":"19008","DOI":"10.1038\/srep19008","article-title":"Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists","volume":"6","author":"Sepe","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jchromb.2024.124296_b0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/cpdd.905","article-title":"Comparison of the Pharmacokinetics of generic versus branded Obeticholic acid in a Chinese population: effects of food and sex","volume":"10","author":"Li","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev"},{"key":"10.1016\/j.jchromb.2024.124296_b0015","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/17474124.2016.1216784","article-title":"Obeticholic acid for the treatment of primary biliary cirrhosis","volume":"10","author":"Jones","year":"2016","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jchromb.2024.124296_b0020","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000444544","article-title":"Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis","volume":"34","author":"Chazouill\u00e8res","year":"2016","journal-title":"Dig. Dis."},{"key":"10.1016\/j.jchromb.2024.124296_b0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/bmb\/ldaa006","article-title":"Obeticholic acid-a new therapy in PBC and NASH","volume":"133","author":"Chapman","year":"2020","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.jchromb.2024.124296_b0030","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cld.1076","article-title":"Obeticholic acid for the treatment of nonalcoholic steatohepatitis","volume":"17","author":"Ratziu","year":"2021","journal-title":"Clin Liver Dis (hoboken)"},{"key":"10.1016\/j.jchromb.2024.124296_b0035","doi-asserted-by":"crossref","first-page":"20316","DOI":"10.1007\/s11356-019-05398-2","article-title":"Metabolism of obeticholic acid in brown bullhead (Ameiurusnebulosus)","volume":"26","author":"Mach","year":"2019","journal-title":"Environ. Sci. Pollut. Res. Int."},{"unstructured":"FDA, Prescribing information for OCALIVA (obeticholic acid), 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/207999s000lbl.pdf. Accessed 10 January 2019.","key":"10.1016\/j.jchromb.2024.124296_b0040"},{"key":"10.1016\/j.jchromb.2024.124296_b0045","first-page":"2070","article-title":"Metabolism of ursodeoxycholic acid in human raises challenges to its bioequivalence studies","volume":"9","author":"Ding","year":"2020","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.jchromb.2024.124296_b0050","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/cts.12468","article-title":"Metabolic profile of obeticholic acid and endogenous bile acids in rats with decompensated liver cirrhosis","volume":"10","author":"Roda","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jchromb.2024.124296_b0055","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cts.12421","article-title":"Modeling and experimental studies of obeticholic acid exposure and the impact of cirrhosis stage","volume":"9","author":"Edwards","year":"2016","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jchromb.2024.124296_b0060","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/jssc.202001050","article-title":"A novel LC-MS\/MS method for simultaneous estimation of obeticholic acid, glyco-obeticholic acid, tauro-obeticholic acid in human plasma and its application to a pharmacokinetic study","volume":"44","author":"Valluri","year":"2021","journal-title":"J. Sep. Sci."},{"unstructured":"US Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation, 2018, https:\/\/www.fda.gov\/media\/70858\/download.","key":"10.1016\/j.jchromb.2024.124296_b0065"},{"unstructured":"European Medicines Agency, Guideline on Bioanalytical Method Validation, 2011. http:\/\/www.ema.europa.eu\/docs\/en.GB\/documentlibrary\/Scientifcguideline\/2011\/08\/WC500109686.pdf.","key":"10.1016\/j.jchromb.2024.124296_b0070"},{"key":"10.1016\/j.jchromb.2024.124296_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123275","article-title":"Determination of free and encapsulated cytarabine and daunorubicin in ratplasma after intravenous administration of liposomal formulation usingultra-high performance liquid chromatography tandem mass spectrometry","volume":"1200","author":"Li","year":"2022","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2024.124296_b0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jchromb.2019.05.011","article-title":"An ultra-performance liquid chromatography-tandem mass spectrometrymethod for the determination of obeticholic acid in rat plasma and itsapplication in preclinical pharmacokinetic studies","volume":"1121","author":"Li","year":"2019","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2024.124296_b0085","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/liv.15816","article-title":"Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH","volume":"44","author":"Alkhouri","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.jchromb.2024.124296_b0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/DDDT.S289016","article-title":"Bioequivalence and pharmacokinetic profiles of generic and branded obeticholic acid in healthy Chinese subjects under fasting and fed conditions","volume":"15","author":"Wang","year":"2021","journal-title":"Drug Des. Devel. Ther."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224003052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224003052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T05:05:06Z","timestamp":1726376706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023224003052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":18,"alternative-id":["S1570023224003052"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124296","relation":{},"ISSN":["1570-0232"],"issn-type":[{"type":"print","value":"1570-0232"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous determination of Obeticholic acid and its two major metabolites in human plasma after administration of Obeticholic acid tablets using ultra-high performance liquid chromatography tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124296"}}